BeiGene, a global biotechnology company, and DualityBio, a next-generation ADC company, entered an agreement for BeiGene to acquire an exclusive option for a global clinical and commercial license to an investigational, preclinical ADC therapy for patients with select solid tumors. DualityBio will receive an upfront payment, and will be eligible for additional payments upon BeiGene exercising its option, based upon the achievement of certain development, regulatory, and commercial milestones,...